PMID- 25908035
OWN - NLM
STAT- MEDLINE
DCOM- 20150929
LR  - 20181203
IS  - 2038-2529 (Electronic)
IS  - 0300-8916 (Linking)
VI  - 101
IP  - 3
DP  - 2015 May-Jun
TI  - Helical tomotherapy for the treatment of anal canal cancer: a dosimetric 
      comparison with 3D conformal radiotherapy.
PG  - 268-72
LID - 10.5301/tj.5000269 [doi]
AB  - AIMS AND BACKGROUND: The standard treatment of anal canal cancer (ACC) is 
      combined chemotherapy and radiation therapy (RT), which is complex because of the 
      shape of the target volumes and the need to minimize the irradiation of normal 
      pelvic structures. In this study we compared the dosimetric results of helical 
      tomotherapy (HT) plans with traditional 3D conformal RT (3DRT) plans for the 
      treatment of ACC. METHODS AND STUDY DESIGN: Twelve patients (median age 57 years, 
      range 38-83; F/M 8/4) treated with HT and concurrent chemotherapy for locally 
      advanced ACC were selected. All had histologically confirmed squamous-cell 
      carcinoma. A clinical target volume including the tumor and pelvic and inguinal 
      lymph nodes was treated with HT to a total dose of 36 Gy in 1.8-Gy daily 
      fractions. Then a sequential boost of 23.4 Gy in 1.8-Gy daily fractions (total 
      dose 59.4 Gy) was delivered to the tumor and involved nodes. For all 12 patients, 
      3DRT plans were generated for comparison. Treatment plans were evaluated by means 
      of standard dose-volume histograms. Dose coverage of the planning target volumes 
      (PTVs), homogeneity index (HI), and mean doses to organs at risk (OARs) were 
      compared. RESULTS: The coverage of PTV was comparable between the two treatment 
      plans. HI was better in the HT vs. 3DRT plans (1.25 and 3.57, respectively; 
      p<0.0001). HT plans resulted in better sparing of OARs (p<0.0001). 
      CONCLUSIONS: HT showed superior target dose conformality and significant sparing 
      of pelvic structures compared with 3DRT. Further investigation should determine 
      if these dosimetric improvements will improve clinical outcomes regarding 
      locoregional control, survival, and treatment-related acute and late morbidity.
FAU - Ugurluer, Gamze
AU  - Ugurluer G
AD  - 1 Department of Radiation Oncology, University Hospital Center, University of 
      Lausanne, Lausanne - Switzerland.
FAU - Ballerini, Giorgio
AU  - Ballerini G
FAU - Moeckli, Raphael
AU  - Moeckli R
FAU - Matzinger, Oscar
AU  - Matzinger O
FAU - Bourhis, Jean
AU  - Bourhis J
FAU - Ozsahin, Mahmut
AU  - Ozsahin M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20150416
PL  - United States
TA  - Tumori
JT  - Tumori
JID - 0111356
RN  - Anal Canal Carcinoma
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Anus Neoplasms/drug therapy/pathology/*radiotherapy
MH  - Carcinoma, Squamous Cell/drug therapy/pathology/*radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - *Dose Fractionation, Radiation
MH  - Female
MH  - Humans
MH  - *Imaging, Three-Dimensional
MH  - Inguinal Canal
MH  - Lymph Nodes/pathology/radiation effects
MH  - Lymphatic Metastasis/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Organs at Risk/radiation effects
MH  - Radiometry
MH  - Radiotherapy Planning, Computer-Assisted
MH  - *Radiotherapy, Conformal
MH  - *Radiotherapy, Intensity-Modulated
MH  - Treatment Outcome
EDAT- 2015/04/25 06:00
MHDA- 2015/09/30 06:00
CRDT- 2015/04/25 06:00
PHST- 2015/01/14 00:00 [accepted]
PHST- 2015/04/25 06:00 [entrez]
PHST- 2015/04/25 06:00 [pubmed]
PHST- 2015/09/30 06:00 [medline]
AID - 0B0580DF-FE4E-4FD5-862D-3E6407CB811E [pii]
AID - 10.5301/tj.5000269 [doi]
PST - ppublish
SO  - Tumori. 2015 May-Jun;101(3):268-72. doi: 10.5301/tj.5000269. Epub 2015 Apr 16.